Professor Zhengming Chen to present 2019 Archie Cochrane Lecture

Zhengming Chen will present the 2019 Archie Cochrane Lecture

Zhengming Chen will present the 2019 Archie Cochrane Lecture

Green Templeton is pleased to confirm that Zhengming Chen, Professor of Epidemiology at Nuffield Department of Population Health, University of Oxford, will present 2019’s Archie Cochrane Lecture.

The topic for this year’s lecture is Big biobanks in the East and West and it will take place at the EP Abraham Lecture Theatre at Green Templeton on Thursday 14 March at 18:00.

Many important genetic and non-genetic causes of major diseases still await discovery, and several big blood-based prospective studies have been undertaken this century, including at the China Kadoorie Biobank (CKB) and UK Biobank, both based in Oxford.

Major findings are now emerging in CKB, some expected and some intriguingly unexpected but novel, including assessment of any causal protective effects of moderate alcohol drinking on stroke and heart disease using the East Asian specific “flushing” genes.

The big maturing biobanks in the Eastern and Western populations with different lifestyles, environments and genetic architectures will greatly improve our understanding about the aetiology of many diseases.

This event is free to attend and open to everyone.

> Registration for tickets is NOW OPEN HERE.

Professor Chen has a long connection with Green Templeton; in 1987 he came to then-Green College to analyse the Shanghai Factory Workers cohort, before pursuing a DPhil study in Oxford based on the Shanghai cohort data he brought with him.

He previously studied medicine at Shanghai Medical University in China. His main research has focused on the determinants of chronic disease and development of evidence-based medicine.

Since mid-1990s, Professor Chen has conducted several large randomised trials of treatment for MI, stroke and cancer in China, totalling more than 100,000 patients. These trials not only generated important findings that have changed the clinical practice worldwide, but also helped establish the tradition of large randomised trials in China.

He initiated and established the CKB and has been the Lead Principal Investigator, together with Professor Liming Li in China, since its inception in 2003. CKB will continue indefinitely and the large range of exposure and disease outcome data collected or to be generated will lead to many novel findings over the next few decades.

Created: 06 February 2019